

**4<sup>th</sup> Evolving concepts in Complete Response to Neoadjuvant Therapy for Rectal Cancer  
22<sup>nd</sup> March 2017**

**Convened by Prof Bill Heald and Mr Brendan Moran  
At Pelican Cancer Foundation, Basingstoke RG24 9NN**

08.15 Registration

**Aim of the meeting:** *Is the time right to actively look for a cCR. How does this manifest itself in clinical practice? What are the challenges in making those decisions? How to report cCR in a consistent and uniform manner*

**Chair: Prof Bill Heald**

08.30 Welcome and introduction

Prof B Heald

08.45 The evolution and development of the concept

Prof A Habr-Gama

09.10 The patients view

tbc

09.25 Questions

**Chair Geerard Beets**

09.35 When not to operate – an oncologists perspective

Dr Carlos Cavarlho

09.50 pCR – How do we know and what does it mean? Is it really a tragedy?

Prof Phil Quirke

10.05 Discussion

10.15 Coffee

**Chair: Brendan Moran**

**Update session**

No introduction of the complete response concept - This will have been done by Angelita Habr-Gama  
Each speaker has 3 slides and 10 minutes

- Brief summary of main results from each unit (10 mins)
  1. What we call it all in our unit
  2. Neo-adjuvant CRT regime – indications, dose, and protocol
  3. Timing of assessment after neo-adjuvant CRT and modalities used
  4. Number of patients under surveillance
  5. Surveillance protocol after cCR
  6. Outcomes
    - Re-growth rate
    - Recurrence rate
    - Salvage rate (and surgical outcomes)
    - DFS

10.45 Dr Phil Paty

10.55 Prof Anders Jakobsen

11.05 Prof Geerard Beets

11.15 Mr Rodrigo Perez

11.25 Prof Andrew Renehan

11.35 Prof Arthur Sun Myint

11.45 Dr Diana Tait

11.55 Discussion

12.15 **Consensus** and Voting - background and agreement – Mr Mit Dattani and Mr Brendan Moran

- 13.00 Lunch
- 13.45 Consent and informed consent - where does complete response sit? Mr Rob Wheeler  
Discussion
- Chair: Prof Anders Jakobson**
- 14.10 Radiotherapy options for maximising response – The more the better? Dr Oriol Pares  
*A review of current radiotherapy options? Can we increase the dose? How safe is it? Any role for endoluminal boost? Newer technologies (IMRT)*
- 14.25 A review of current neo-adjuvant CRT regimes Dr Mark Harrison  
*How do we maximise response? Does systemic chemotherapy help? And should it be given before (induction or consolidation) or after a cCR? Is a change from recommended indications for neo-adjuvant treatment ever justified?*
- 14.40 Discussion
- Chair: Mr Nuno Figueiredo**
- 14.50 Case study and voting Mr Mit Dattani
- Chair: Dr Phil Paty**
- 15.20 How to evaluate response following CRT Prof Geerard Beets  
*Define a cCR. The evidence for clinical, endoscopic and radiological assessment. Pitfalls in assessment. Equivocal cases – how to decide?*
- 15.35 The near complete response – a new dilemma? Mr Rodrigo Perez  
*When do you assess response to neo-adjuvant CRT? Waiting a bit more – how long is long enough? What do we do with the “near” complete responders? Is a local excision oncologically safe and justified?*
- 15.50 Discussion
- 16.00 Tea
- Chair: Andrew Renehan**
- 16.15 Persisting residual mucosal abnormalities and biopsies Dr Phil Paty  
*What should we do with equivocal cases? Should we be worried about mucosal ulcers? The role of biopsies?*
- 16.30 How to monitor a cCR – is there such a thing as too much surveillance? Prof Gina Brown  
*The optimal surveillance strategy - RMH protocol. How to monitor response on MRI. The evidence for mrTRG grading. How useful is a PET-CT or DWI?*
- 16.45 Discussion
- 17.00 Summary and take home messages